206 related articles for article (PubMed ID: 32621557)
21. Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure.
Marso SP; Baeres FMM; Bain SC; Goldman B; Husain M; Nauck MA; Poulter NR; Pratley RE; Thomsen AB; Buse JB;
J Am Coll Cardiol; 2020 Mar; 75(10):1128-1141. PubMed ID: 32164886
[TBL] [Abstract][Full Text] [Related]
22. Glycated hemoglobin variability and the risk of cardiovascular events in patients with prediabetes and type 2 diabetes mellitus: A post-hoc analysis of a prospective and multicenter study.
Manosroi W; Phimphilai M; Waisayanand N; Buranapin S; Deerochanawong C; Gunaparn S; Phrommintikul A; Wongcharoen W;
J Diabetes Investig; 2023 Dec; 14(12):1391-1400. PubMed ID: 37610280
[TBL] [Abstract][Full Text] [Related]
23. Relationship of glycated haemoglobin and reported hypoglycaemia to cardiovascular outcomes in patients with type 2 diabetes and recent acute coronary syndrome events: The EXAMINE trial.
Heller SR; Bergenstal RM; White WB; Kupfer S; Bakris GL; Cushman WC; Mehta CR; Nissen SE; Wilson CA; Zannad F; Liu Y; Gourlie NM; Cannon CP;
Diabetes Obes Metab; 2017 May; 19(5):664-671. PubMed ID: 28058763
[TBL] [Abstract][Full Text] [Related]
24. International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.
Bhatt AS; Luo N; Solomon N; Pagidipati NJ; Ambrosio G; Green JB; McGuire DK; Standl E; Cornel JH; Halvorsen S; Lopes RD; White HD; Holman RR; Peterson ED; Mentz RJ;
Am Heart J; 2019 Dec; 218():57-65. PubMed ID: 31707329
[TBL] [Abstract][Full Text] [Related]
25. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Cornel JH; Bakris GL; Stevens SR; Alvarsson M; Bax WA; Chuang LM; Engel SS; Lopes RD; McGuire DK; Riefflin A; Rodbard HW; Sinay I; Tankova T; Wainstein J; Peterson ED; Holman RR;
Diabetes Care; 2016 Dec; 39(12):2304-2310. PubMed ID: 27742728
[TBL] [Abstract][Full Text] [Related]
26. Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Reed SD; Li Y; Leal J; Radican L; Adler AI; Alfredsson J; Buse JB; Green JB; Kaufman KD; Riefflin A; Van de Werf F; Peterson ED; Gray AM; Holman RR;
Diabetes Obes Metab; 2018 Jul; 20(7):1732-1739. PubMed ID: 29573215
[TBL] [Abstract][Full Text] [Related]
27. Glycated Hemoglobin Variability Is Associated With Adverse Outcomes in Patients With Heart Failure Irrespective of Diabetic Status.
Xu X; Ren QW; Chandramouli C; Ng MY; Tsang CT; Tse YK; Li XL; Liu MY; Wu MZ; Huang JY; Cheang IF; Yang JF; Wang F; Lam CSP; Yiu KH
J Am Heart Assoc; 2024 May; 13(9):e034109. PubMed ID: 38686852
[TBL] [Abstract][Full Text] [Related]
28. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
[TBL] [Abstract][Full Text] [Related]
29. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide.
Gerstein HC; Colhoun HM; Dagenais GR; Diaz R; Lakshmanan M; Pais P; Probstfield J; Riddle MC; Rydén L; Xavier D; Atisso CM; Avezum A; Basile J; Chung N; Conget I; Cushman WC; Franek E; Hancu N; Hanefeld M; Holt S; Jansky P; Keltai M; Lanas F; Leiter LA; Lopez-Jaramillo P; Cardona-Munoz EG; Pirags V; Pogosova N; Raubenheimer PJ; Shaw J; Sheu WH; Temelkova-Kurktschiev T;
Diabetes Obes Metab; 2018 Jan; 20(1):42-49. PubMed ID: 28573765
[TBL] [Abstract][Full Text] [Related]
30. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
Scirica BM; Im K; Murphy SA; Kuder JF; Rodriguez DA; Lopes RD; Green JB; Ruff CT; Sabatine MS
Clin Cardiol; 2022 Jul; 45(7):794-801. PubMed ID: 35715946
[TBL] [Abstract][Full Text] [Related]
31. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c.
Cavender MA; Scirica BM; Raz I; Steg PG; McGuire DK; Leiter LA; Hirshberg B; Davidson J; Cahn A; Mosenzon O; Im K; Braunwald E; Bhatt DL
Am J Med; 2016 Mar; 129(3):340.e1-8. PubMed ID: 26524706
[TBL] [Abstract][Full Text] [Related]
32. Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Davis TME; Mulder H; Lokhnygina Y; Aschner P; Chuang LM; Raffo Grado CA; Standl E; Peterson ED; Holman RR;
Diabetes Obes Metab; 2018 Jun; 20(6):1427-1434. PubMed ID: 29405540
[TBL] [Abstract][Full Text] [Related]
33. Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial.
Segar MW; Patel KV; Vaduganathan M; Caughey MC; Butler J; Fonarow GC; Grodin JL; McGuire DK; Pandey A
Diabetes Care; 2020 Aug; 43(8):1920-1928. PubMed ID: 32540922
[TBL] [Abstract][Full Text] [Related]
34. [TECOS: confirmation of the cardiovascular safety of sitaliptin].
Scheen AJ; Paquot N
Rev Med Liege; 2015 Oct; 70(10):511-6. PubMed ID: 26727841
[TBL] [Abstract][Full Text] [Related]
35. Dulaglutide and cardiovascular and heart failure outcomes in patients with and without heart failure: a post-hoc analysis from the REWIND randomized trial.
Branch KRH; Dagenais GR; Avezum A; Basile J; Conget I; Cushman WC; Jansky P; Lakshmanan M; Lanas F; Leiter LA; Pais P; Pogosova N; Raubenheimer PJ; Ryden L; Shaw JE; Sheu WHH; Temelkova-Kurktschiev T; Bethel MA; Gerstein HC; Chinthanie R; Probstfield JL
Eur J Heart Fail; 2022 Oct; 24(10):1805-1812. PubMed ID: 36073143
[TBL] [Abstract][Full Text] [Related]
36. Hemoglobin A1c predicts heart failure hospitalization independent of baseline cardiac function or B-type natriuretic peptide level.
Kishimoto I; Makino H; Ohata Y; Tamanaha T; Tochiya M; Kada A; Ishihara M; Anzai T; Shimizu W; Yasuda S; Ogawa H
Diabetes Res Clin Pract; 2014 May; 104(2):257-65. PubMed ID: 24629410
[TBL] [Abstract][Full Text] [Related]
37. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
[TBL] [Abstract][Full Text] [Related]
38. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
[TBL] [Abstract][Full Text] [Related]
39. Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics.
Htoo PT; Tesfaye H; Schneeweiss S; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Najafzadeh M; Koeneman L; Farsani SF; Déruaz-Luyet A; Paik JM; Patorno E
JAMA Netw Open; 2022 Oct; 5(10):e2237606. PubMed ID: 36264574
[TBL] [Abstract][Full Text] [Related]
40. Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
De Ferrari GM; Stevens SR; Ambrosio G; Leonardi S; Armstrong PW; Green JB; Wamil M; Holman RR; Peterson ED;
Am Heart J; 2020 Feb; 220():82-88. PubMed ID: 31790905
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
